SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application in post-TKI EGFR-mutated lung cancer, citing the lack of a statistically significant overall-survival benefit despite a progression-free-survival benefit. Traders are debating the setbacks wider impact: bears focus on the rejection and selling pressure, while bulls argue it is limited to this indication and point to HARMONi-3 and the broader pipeline as remaining drivers.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas pivotal Phase 3 APPROACH readout for HLP003 in major depression, a binary clinical catalyst that traders are weighing against the companys dilution and governance concerns. Bulls emphasize the potential of its adjunctive treatment approach, while skeptics question whether the trial data will deliver; claims about the results remain unverified in the discussion.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers quarterly results are driving attention: revenue and adjusted earnings beat expectations, and the company raised its revenue outlook, while lower EPS guidance tied to licensing charges tempered the reaction. Traders are weighing the strong growth-portfolio performance against licensing costs and longer-term patent-cliff concerns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Positive interim results from Alpha Taus REGAIN trial in recurrent glioblastoma are driving attention: all treated patients were reported alive, with objective responses in the six evaluable patients. Traders are enthusiastic about the early signal and its potential implications, while some stress that the small cohort needs longer follow-up to clarify durability and safety.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,407,563,191.01116 in circulation. The last known price of Stellar is 0.13466341 USD and is down -7.69 over the last 24 hours. It is currently trading on 849 active market(s) with $286,159,144.84 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention amid a sharp selloff and a modest rebound, with traders split between buying the dip and warning of further downside and continued selling pressure. Some cite Stellars real-world-asset tokenization activity and DTCC plans as longer-term positives, while skeptics question whether adoption will translate into gains for the token.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

A nationwide FAA communications outage has drawn scrutiny to L3Harriss role in the air-traffic network, with officials investigating whether a router defect or installation issue contributed. Traders are debating potential fallout and liabilitysome expect pressure on the stock, while others argue L3Harris may be a scapegoat and view the dip as a buying opportunity.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is drawing attention after quarterly results topped estimates and the company raised its full-year revenue outlook, while traders focus on oncology progressespecially pumitamigas it shifts beyond COVID vaccines. Bulls see promise in the pipeline, while skeptics question clinical execution and compare its progress unfavorably with Moderna.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Vikings ObesityWeek VK2735 analyseshighlighting BMI-category improvements and cardiometabolic benefitsare drawing interest, alongside speculation about a Big Pharma partnership or buyout. Bulls see the data and obesity-drug pipeline as valuable, while skeptics note the analyses are not new Phase 3 results and say deal rumors remain unconfirmed.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Targets stronger-than-expected quarterly results and raised outlook have fueled discussion of a turnaround, with traders pointing to improving traffic and comparable sales. The reaction is divided: bulls see momentum in the recovery, while skeptics note that one-time tariff refunds boosted reported profit and question how durable the gains are.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Speculation that Nvidia CEO Jensen Huang could return is driving hopes for a broader tech-led rebound, with traders also watching Nvidia earnings and the Anthropic IPO. Others doubt the comeback rumor and point to market weakness, macro risks, and volatility as reasons for caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$XRTX gained a Japanese patent for its XRx-101 program.

Taxidriver

StockTwits Web

XORTX Therapeutics Inc

 gained a Japanese patent for its XRx-101 program.